At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniacombination
Likely dose
Not stated in record
Key inclusion· 3
- ✓Confirmed diagnosis of schizophrenia
- ✓No history of relapse and hospitalization
- ✓Currently receiving ambulatory psychiatric treatment
Key exclusion· 3
- ✕Other psychotic disorders (non-schizophrenia)
- ✕Active relapse or current hospitalization
- ✕Active substance abuse
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training in Schizophrenia and Treatment Resistant Schizophrenia. This is a Non-randomized Trial. The Therapy Lasts 60 Sessions.
In Brief
A Phase 2 clinical trial evaluating The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia for Schizophrenia. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia. Is it effective and efficacious?
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesGreece
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartNov 2022
First PostedNov 2022
Primary CompletionMar 2024
TodayJul 2026
First PostedNov 21, 2022
Enrollment StartNov 1, 2022
Primary CompletionMar 26, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.6 years ago
Interventions
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniacombination
The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.